From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.41
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 2.36
Pain Relevance 0.33

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

protein modification process (MSRA) mitochondrion (MSRA) oxidoreductase activity (MSRA)
aging (MSRA) nucleus (MSRA) cytoplasm (MSRA)
Anatomy Link Frequency
basal cell 1
MSRA (Homo sapiens)
Pain Link Frequency Relevance Heat
aspirin 4 77.32 Quite High
cINOD 6 76.08 Quite High
Inflammation 12 66.04 Quite High
cytokine 8 62.92 Quite High
chemokine 1 56.24 Quite High
adenocard 2 5.00 Very Low Very Low Very Low
COX2 1 5.00 Very Low Very Low Very Low
Hsan 1 5.00 Very Low Very Low Very Low
member 8 1 5.00 Very Low Very Low Very Low
Inflammatory response 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Basal Cell Nevus Syndrome 5 98.16 Very High Very High Very High
Toxicity 1 97.76 Very High Very High Very High
Skin Cancer 19 97.16 Very High Very High Very High
Breast Cancer 55 96.62 Very High Very High Very High
Cancer 60 95.86 Very High Very High Very High
Lung Cancer 14 89.12 High High
Stress 36 81.24 Quite High
Diabetes Mellitus 4 72.12 Quite High
Insulin Resistance 3 71.32 Quite High
Colon Cancer 11 69.52 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Methionine sulfoxide reductase A (MsrA) is specific for methionine(S)sulfoxide and MsrB is specific for methionine(R)sulfoxide.
Negative_regulation (reductase) of MsrA
1) Confidence 0.41 Published 2010 Journal Biol Trace Elem Res Section Body Doc Link PMC2855032 Disease Relevance 0.39 Pain Relevance 0.18
To determine whether the enhanced killing of sulindac-treated cancer cells by TBHP involved reduction of sulindac to sulindac sulfide, the active inhibitor of cyclooxygenases, the experiments described above were repeated using sulindac sulfone, which is not a substrate for MsrA (unpublished data) or a COX inhibitor [28].
Negative_regulation (inhibitor) of MsrA associated with cancer
2) Confidence 0.32 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2686156 Disease Relevance 0.96 Pain Relevance 0.15
ATCC: American Type Culture Collection; BC: Breast carcinoma; BCC: basal cell carcinoma; CGH: Comparative Genomic Hybridization; Chr.: Chromosome; HD: Homozygous deletion; HED: Hemizygous deletion; IHC: Immunohistochemisty; LOH: loss of heterozygosity; MSRA: Methylation Sensitive Restriction Analysis; NBCCS: nevoid basal cell carcinoma syndrome; NER: nucleotide excision repair; Q-PCR: Quantitative Real-time Polymerase Chain Reaction; SCC: squamous cell carcinoma; UICC: International Union against Cancer

Competing interests

Negative_regulation (loss) of MSRA in basal cell associated with basal cell nevus syndrome, cancer, breast cancer and skin cancer
3) Confidence 0.07 Published 2008 Journal Mol Cancer Section Body Doc Link PMC2633285 Disease Relevance 1.01 Pain Relevance 0

General Comments

This test has worked.

Personal tools